Anticipating the possible objections that could be raised by the European and US authorities regarding its plan to merge with its rival AVENTIS, the French laboratory SANOFI has announced the conclusion of an agreement with the British giant GSK-GLAXOSMITHKLINE whereby the latter will, after payment of EUR 453 million, become the world-wide owner of two of its medicinal products, arixtra and fraxiparine. The deal is subject to a successful bid on AVENTIS shares and to approval from the...